Ongoing important trials
LEAP-012 — pembrolizumab + lenvatinib + TACE in intermediate HCC
Pembrolizumab Plus Lenvatinib Plus TACE Versus TACE in Intermediate-Stage HCC (LEAP-012)
- Phase
- Phase III
- Recruitment
- Terminated
- Results maturity
- Interim analysis
- Publication
- Peer-reviewed
- Regulatory approval
- No regulatory approval
- NCT
- NCT04246177
- Registry checked
- 2026-10-29
- Editorial update
- 2026-10-29
Not a treatment recommendation. Experimental or ongoing research does not by itself replace standard care.
For patients
What is being studied? Adding immunotherapy and a targeted drug to local liver treatment is being studied.
What did it show? Randomized evaluation of adding systemic IO+TKI to locoregional therapy; PFS improved, no OS claim.
What is not proven? Transfer to early/advanced HCC; net benefit without toxicity.
Is this standard care today? This listing alone does not replace standard care; approval and guideline context require clinician judgment.
For clinicians
Lancet 2025 LEAP-012: median PFS 14.6 vs 10.0 mo. Terminated on CT.gov; PFS ≠ OS. Cross-read with HCC Landmark.
Cancer / population: Liver (HCC) — Ara evre HCC (TACE adayı)
Intervention: Pembrolizumab + lenvatinib + TACE
Primary endpoint: PFS / OS (protokol)
Source-verified summary: PFS 14,6 vs 10,0 ay (Lancet 2025). OS üstünlüğü bu karttan iddia edilmez; çalışma sonlandırıldı.
Limitations: Ara evre seçimi kritik; toksisite yönetimi; OS iddiası yok.